Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor

US10093656B2 · kind B2 · utility

Assignee

• NANJING SANHOME PHARMACEUTICAL CO., LTD. · CN

Inventors

• Charles Z. Ding · San Mateo, US
• Shuhui CHEN · Shanghai, CN
• Baoping Zhao · Shanghai, CN
• Xile LIU · Shanghai, CN
• Linxia Xiao · Shanghai, CN
• Chao Ding · Nanhu, CN
• Fei Wang · Beijing, CN
• Jian Li · Shanghai, CN

Key dates

• Filing date: Nov 14, 2017
• Grant date: Oct 9, 2018
• Expiry date: Nov 14, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed is a fused-ring or tricyclic aryl pyrimidine compound used as a mutation selectivity EGFR inhibitor. Specifically, disclosed is a compound represented by formula (I) and used as an EGFR inhibitor or a pharmaceutically acceptable salt thereof.